ERBB2 and breast cancer: Triple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BCs) and is defined by a lack of estrogen and progesterone receptor expression and the absence of ERBB2 gene amplification, which encodes human epidermal growth factor receptor 2 (HER2) [1].